For the quarter ending 2026-03-31, NAUT had $2,238K increase in cash & cash equivalents over the period. -$13,610K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -14,697 | -13,781 | -13,574 | -31,646 |
| Stock-based compensation | 1,362 | 1,471 | 1,496 | 3,877 |
| Amortization of operating lease right-of-use assets | 1,142 | 1,183 | 1,193 | 2,336 |
| Depreciation | - | 1,753 | - | - |
| In-process research and development | - | 0 | - | - |
| Depreciation | -1,014 | - | 426 | 922 |
| Amortization (accretion) of premiums (discounts) on securities, net | 68 | 134 | 306 | 980 |
| Prepaid expenses and other assets | 355 | -395 | 11 | -160 |
| Accounts payable | 200 | 2 | -20 | -51 |
| Accrued expenses and other liabilities | 128 | -703 | 942 | 390 |
| Operating lease liabilities | -1,146 | -1,213 | -1,180 | -2,295 |
| Net cash used in operating activities | -13,100 | -12,375 | -11,034 | -27,287 |
| Proceeds from maturities of securities | 25,805 | 34,750 | 28,363 | 45,878 |
| Purchases of securities | 11,062 | 33,719 | 27,493 | 11,278 |
| Purchases of property and equipment | 510 | 244 | 418 | 615 |
| Cash paid in connection with asset acquisition | - | 0 | - | - |
| Net cash provided by investing activities | 14,233 | 787 | 452 | 33,985 |
| Proceeds from issuance of common stock under employee stock purchase plan | - | 69 | 0 | 87 |
| Proceeds from exercise of stock options | 1,105 | 32 | 0 | 26 |
| Net cash provided by financing activities | 1,105 | 101 | 0 | 113 |
| Net increase in cash, cash equivalents and restricted cash | 2,238 | -11,487 | -10,582 | 6,811 |
| Cash, cash equivalents and restricted cash at beginning of period | 13,390 | 24,877 | 28,648 | - |
| Cash, cash equivalents and restricted cash at end of period | 15,628 | 13,390 | 24,877 | - |
Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology, Inc. (NAUT)